SCHEMBL16225652

SCHEMBL16225652

COc1cc(O)c2c(c1)C(=O)c1cc(C(=O)O)cc(O)c1C2=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.69
MAPT P10636 5/20 0.69
CYP3A4 P08684 4/20 0.69
POLB P06746 4/20 0.69
HPGD P15428 3/20 0.69
RECQL P46063 3/20 0.69
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
TDP1 Q9NUW8 3/20 0.69
MAPK1 P28482 3/20 0.69
APEX1 P27695 2/20 0.69
PKM P14618 1/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
KDM4E B2RXH2 4/20 0.66
ELANE P08246 4/20 0.66
ALOX15 P16050 3/20 0.66
GLA P06280 1/20 0.66
LMNA P02545 3/20 0.60
TTR P02766 2/20 0.60
THRB P10828 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16226983 0.87 ELANE (0.83) ALDH1A1MAPTCYP3A4POLBHPGD
Lunatin SCHEMBL16226694 0.82 ELANE (0.76) ALDH1A1MAPTCYP3A4POLBHPGD
Emodic Acid SCHEMBL5073407 0.82 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4POLBHPGD
Emodic Acid SCHEMBL29360148 0.82 ALDH1A1 (1.00) ALDH1A1MAPTCYP3A4POLBHPGD
Lunatin SCHEMBL30761640 0.82 ELANE (0.76) ALDH1A1MAPTCYP3A4POLBHPGD
SCHEMBL16226554 0.82 ELANE (0.62) ALDH1A1MAPTCYP3A4POLBHPGD
SCHEMBL14345807 0.82 ALDH1A1 (0.73) ALDH1A1MAPTCYP3A4POLBHPGD
SCHEMBL16225641 0.81 ALDH1A1 (0.73) ALDH1A1MAPTCYP3A4POLBHPGD
SCHEMBL28243779 0.80 MAPT (0.63) ALDH1A1MAPTCYP3A4POLBHPGD
SCHEMBL18601968 0.80 ALDH1A1 (0.71) ALDH1A1MAPTCYP3A4POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368695-A1 Atranorin biosynthesis gene derived from lichens and uses thereof INDUSTRY ACADEMIC COOPERATION FOUNDATION OF SUNCHON NATIONAL UNIV (KR) 2025-12-04 US disclosed
US-20230002258-A1 SYSTEMS AND METHODS FOR OXIDIZING DISINFECTANTS COMBINED WITH MOVING BED BIOFILM REACTORS Headworks Bio, Inc. 2023-01-05 US disclosed
WO-2022260402-A1 ATRANORIN BIOSYNTHESIS GENE DERIVED FROM LICHEN AND USE THEREOF 순천대학교 산학협력단 2022-12-15 WO disclosed
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER THE GENERAL HOSPITAL CORPORATION (US) 2014-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER IL2RA, CD74, IL2 ALDH1A1 1004/4885MAPT 3619/4885CYP3A4 2240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.